SLC5A2 and diabetes mellitus: These findings suggest that SGLT2 inhibitors have a dual therapeutic benefit in the management of diabetes: they selectively and reversibly inhibit SGLT2 activity and increase H2S levels, which, in turn, suppresses SGLT2 expression.